Furthermore, disruptions to the cellular activity of DNMT3A, p53, or TDG have been implicated in human cancers such as AML, and we have shown in previous work that clinically identified mutations in p53 disrupt the interactions of DNMT3A with additional partner proteins (3, 40, 41, 42). Here, DNMT3A is linked to cancer.